Reflect on the provided data and tweets to anticipate if the closing price of $bmy is going to increase or decrease at 2017-09-13. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-08-29,-0.9,0.3,-1.2,0.5,0.5,-0.8,-2.0,-2.2,-2.9,-3.4,-3.8
2017-08-30,-0.9,0.5,-0.9,0.9,0.9,-1.2,-2.5,-2.9,-3.4,-4.0,-4.4
2017-08-31,-1.4,0.4,-1.4,1.9,1.9,-2.2,-3.7,-4.2,-4.8,-5.4,-5.8
2017-09-01,0.8,1.3,-0.3,-1.0,-1.0,-0.8,-2.2,-2.9,-3.5,-4.1,-4.7
2017-09-05,-0.5,0.7,-0.7,-0.2,-0.2,-0.2,-1.5,-2.5,-3.1,-3.8,-4.3
2017-09-06,0.2,0.7,-0.2,0.1,0.1,0.0,-1.2,-2.4,-2.9,-3.6,-4.2
2017-09-07,-3.7,1.0,-3.7,5.0,5.0,-3.6,-5.1,-6.5,-7.1,-7.7,-8.4
2017-09-08,0.2,0.9,-0.6,-0.4,-0.3,-2.6,-4.1,-5.5,-6.3,-6.9,-7.6
2017-09-11,-0.2,0.7,-0.9,0.2,0.2,-1.8,-3.5,-5.0,-5.9,-6.6,-7.3
2017-09-12,-0.9,0.1,-1.0,0.5,0.5,-1.3,-3.3,-4.8,-6.0,-6.7,-7.5

2017-08-29: pfizer presents encouraging eliquis results in nvaf patients $pfe also $bmy $jnj $ptla |celgene $celg ebitda multiple of 24.8x doesn't look attractive vs peers: $bmy $abbv $mrk $shpg $amgn¡­ |$bmy aft
2017-08-30: $halo (hyaluronidase) with cancer drugs, is like lemon (citric acid) with water/tea. increases absorption of liquids. $mrk $lly $bmy $nvs|see which one we favor and our email alert stats $orcl $cop $n
2017-08-31: what about a bristol-myers squibb takeover by pfizer?  $bmy $pfe|$spy $xlv $gild $pfe $bmy decreased promotion could further undermine its #insurance markets, which had been struggling $hum $aet $unh|
2017-09-01: rt AT_USER unusual call buying: $nrg 7x average volume, $sqqq 6x, $gild 5x, $gdxj 4x, $jci 4x, $lyb 4x, $bmy 4x, $thc 4x|s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $
2017-09-02: rt AT_USER what does it take to get hired by johnson &amp; johnson $jnj and bristol-myers squibb $bmy?  |opus point partners management boosted bristol myers squibb co $bmy stake by $2.61 million as s
2017-09-03: $mnk granted orphan designation by the fda for cosyntropin for the treatment of duchenne muscular dystrophy.. $ibb $xbi $gsk $nvs $bmy $pfe|bristol myers squibb co $bmy share price declined while fact
2017-09-04: mallinckrodt plc $mnk stake raised by california public employees retirement system $xbi $ibb $spy $bmy|$bmy "bmy potential" on the motley fool message boards: |bristol-myers squibb company $bmy share
2017-09-05: $bmy director dealings: bloomsbury publishing non-executive b¡­ |$oncs ah price up 6% and climbing. new hire happens to have been in charge of m&amp;a's. lol if you can't read between the lines $bmy $
2017-09-06: rt AT_USER $bmy says opdivo multiple myeloma trials are on hold. no surprise given keytruda hold and subsequent fda news. |rt AT_USER following recent $mrk pembro news fda has placed partial clinical 
2017-09-07: rt AT_USER vantage snippet - keytruda¡¯s multiple myeloma fallout has roche in the firing line $mrk $bmy $azn $rhhby |rt AT_USER ipi/nivo beats sunitinib in 1l #kidneycancer by os. $bmy reports on pha
2017-09-08: bristol-myers squibb company $bmy svp joseph c. caldarella sells 9,340 shares |price moves vs expected moves $arry $abbv $mdt $agn $vrx $azn $biib $pfe $teva $bmy $gild $celg¡­ |update: $bmy also rele
2017-09-09: great slide by bmo expected sequence of events for key io trials in 1l-nsclc in 2h17, and our thoughts on implicati¡­ |rt AT_USER #crispr #cas9 offers grt hope for #glaucoma #opthalmology #ai $msft $g
2017-09-10: rt AT_USER presentation of day $bmy lag3 |$bmy heated as it hits the gap, hoping it rests and lest ma's catch up here |$bmy opdivo (nivolumab) demonstrates superior recurrence-free survival versus yer
2017-09-11: this week's most significant #insider trades: september 4-8, 2017 $bby $bmy $dps $f $hal $ph $psec $tjx¡­ |rt AT_USER mon-wed: morgan stanley 150 healthcare webcasts $abbv $agn $alxn $amgn $biib $blue
2017-09-12: s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc  more@ |bristol-myers squibb company $bmy given average rating of ¡°hold¡± by analysts |th
Answer:
Fall